AN2 Therapeutics (ANTX) Amortizatization of Intangibles (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Amortizatization of Intangibles of $81000.0 for Q1 2026, down 81.72% year-over-year from $443000.0 in Q1 2025, and down 30.77% quarter-over-quarter from $117000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Amortizatization of Intangibles for 6 consecutive years, with $81000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 81.72% year-over-year to $81000.0; the TTM figure through Mar 2026 stood at $708000.0 (down 73.09% YoY), while the FY2025 annual figure was $1.1 million, down 67.37% from the prior year.
- Amortizatization of Intangibles eased to $81000.0 in Q1 2026 per ANTX's latest filing, from $117000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.3 million in Q4 2023 and bottomed at -$1000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $469235.3 across 5 years, with a median of $435000.0 in 2023.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 43600.0% — and 2026, when it slumped 81.72%.
- AN2 Therapeutics' Amortizatization of Intangibles stood at $375000.0 in 2022, then jumped by 248.27% to $1.3 million in 2023, then sank by 56.58% to $567000.0 in 2024, then tumbled by 79.37% to $117000.0 in 2025, then tumbled by 30.77% to $81000.0 in 2026.
- Business Quant data shows ANTX's Amortizatization of Intangibles at $81000.0 in Q1 2026, $117000.0 in Q4 2025, and $211000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | 94,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94,000.00 |
| Mar 31, 2026 | 81,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Sep 30, 2025 | 211,000.00 |
| Jun 30, 2025 | 299,000.00 |
| Mar 31, 2025 | 443,000.00 |
| Dec 31, 2024 | 567,000.00 |
| Sep 30, 2024 | 731,000.00 |
| Jun 30, 2024 | 890,000.00 |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | 653,000.00 |
| Jun 30, 2023 | 461,000.00 |
| Mar 31, 2023 | 435,000.00 |
| Dec 31, 2022 | 375,000.00 |
| Sep 30, 2022 | 245,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | -23,000.00 |
| Sep 30, 2021 | -19,000.00 |